871 Construction and evaluation of interleukin 3 (IL3)-zetakine redirected cytolytic T Cells for the treatment of CD123 expressing acute myeloid leukemia

• Sadik Kassim,
• Julian Scherer,
• Rebecca Moeller

Affiliations

Sadik Kassim

Vor Biopharma, Cambridge, MA, USA

Julian Scherer

Vor Biopharma, Cambridge, MA, USA

Rebecca Moeller

Vor Biopharma, Cambridge, MA, USA